AGS67E

Phase 1Completed
0 watching 0 views this week๐Ÿ’ค Quiet
33
Hype Score

Development Stage

โœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Relapsed Lymphoid Malignancy

Conditions

Relapsed Lymphoid Malignancy, Refractory Lymphoid Malignancy

Trial Timeline

Oct 14, 2014 โ†’ Oct 29, 2019

About AGS67E

AGS67E is a phase 1 stage product being developed by Astellas Pharma for Relapsed Lymphoid Malignancy. The current trial status is completed. This product is registered under clinical trial identifier NCT02175433. Target conditions include Relapsed Lymphoid Malignancy, Refractory Lymphoid Malignancy.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (2)

NCT IDPhaseStatus
NCT02610062Phase 1Terminated
NCT02175433Phase 1Completed

Competing Products

20 competing products in Relapsed Lymphoid Malignancy

See all competitors